FDA "Slowdown" Not Shown By Data, But CBER Could Be Affected - Henney

FDA's focus on gene therapy clinical trial oversight could potentially be having an impact on biologic product review times, former FDA Commissioner Jane Henney, MD, acknowledged during a June 12 keynote address at the Goldman Sachs healthcare conference in Dana Point, Calif.